Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
Submitted by
admin
on June 6, 2010 - 12:31pm
Source:
BusinessWire
News Tags:
Eisai
Eribulin Mesylate
breast cancer
Headline:
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
Do Not Allow Advertisers to Use My Personal information
